MAPK1 and histiocytic sarcoma: Histiocytic sarcoma is a rare, aggressive, and poorly understood hematopoietic neoplasm, and the majority of patients diagnosed live only 6 months36. One study found that histiocytic neoplasms might drive the RAF–MEK–ERK pathway and result in the overexpression of MEK137.